Načítá se...

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan

Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Chron Obstruct Pulmon Dis
Hlavní autoři: Horita, Nobuyuki, Kaneko, Takeshi
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4410821/
https://ncbi.nlm.nih.gov/pubmed/25960646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S56067
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!